|Former: Atención Farmacéutica|
|Journal edited by Rasgo Editorial since 1983|
Manuela Velázquez Prieto
EDITOR IN CHIEF
Jaime E. Poquet Jornet
Tomás Casasín Edo
Virginia Hernández Corredoira
Ramón Jódar Masanés
Juan Carlos Juárez Giménez
Volume 19 - Issue 4, July-August 2017
EFECTIVENESS AND SAFETY WITH NEW TREATMENTS IN PANCREATIC CANCER
MAÑES SEVILLA MIREYA, GONZÁLEZ HABA EVA, MARZAL ALFARO MARÍA BELÉN, SÁNCHEZ FRESNEDA MARÍA NORBERTA, ESCUDERO VILAPLANA VICENTE, HERRANZ ALONSO ANA, SANJURJO SÁEZ MARÍA
Background: In recent years, the regimes of chemotherapy based on the administration of Oxaliplatin, Irinotecan, Fluorouracil and Leucovorin (FOLFIRINOX) and Nab-Paclitaxel/Gemcitabine have become therapies of choice in pancreatic cancer (PC).
Objective: To compare the effectiveness and safety of FOLFIRINOX vs Nab-Paclitaxel/Gemcitabine in patients with PC.
Method: Retrospective comparative study of a treatment for adult patients with PC who received FOLFIRINOX and/or Nab-Paclitaxel/Gemcitabine. Effectiveness outcomes were evaluated in terms of progression free survival (PFS) and overall survival (OS). Safety outcomes were evaluated according to the adverse
events (AE) profile from the CTCAE criteria v 4.0.
Results: We analyzed 68 patients, 28 treated with FOLFIRINOX, 40 treated with Nab-Paclitaxel/Gemcitabine. Effectiveness (FOLFIRINOX vs NabP/GZT): PFS (RIC) in first line was 7.13 months (4.23-12.97) vs. 5.43 months (1.7-9.73).
HR for disease progression was 6.98 (p = 0.163). OS (RIC) in first line was 11.4 months (5.9-12.6) vs 9.2 months (4.2-12.2) HR for death was 1.95 (p = 0.414). Safety: 73.52% of patients presented some AE (78% FOLFIRINOX vs 70% NabP/GZT). Grade ≥3 were more frequent in the FOLFIRINOX group.
Conclusions: Patients treated with FOLFIRINOX presented a major PFS and OS. Regarding the safety profile, AE were more frequent and more severe with FOLFIRINOX. As main clinical practice guidelines, we consider FOLFIRINOX to be a standard treatment option for patients with advanced disease and good performance
EFFECTIVENESS – FOLFIRINOX – GEMCITABINE – NAB-PACLITAXEL – PANCREATIC CANCER – SAFETY